Ferring Pharmaceuticals USA
在场
Ferring Pharmaceuticals USA 的所有者是 Ferring Pharmaceuticals.
Ferring Pharmaceuticals 在 3 个国家有直接业务。
高管
查看带有其 12 名主要高管的组织结构图
Ferring Pharmaceuticals USA 搜索最多的简介
- Brent Ragans, President
- Leonardo Silva, Vice President, Global Chief Compliance & Privacy ...
- Asif Mughal, Vice President, Global Quality Assurance
创建提醒
跟踪 Ferring Pharmaceuticals USA 的高管变动
药店
Ferring Pharmaceuticals 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Ferring Pharmaceuticals USA 的最新新闻稿
- Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program - Ferring Pharmaceuticals USA
- Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc Herniation - Ferring Pharmaceuticals USA
- Ferring Appreciates the Support of New Jersey and Minnesota as They Issue Proclamations Recognizing November as C. Difficile Infection Awareness Month for Fifth Consecutive Year - Ferring Pharmaceuticals USA
- Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2024 - Ferring Pharmaceuticals USA
- Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress - Ferring Pharmaceuticals USA
- Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024 - Ferring Pharmaceuticals USA
- Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024 - Ferring Pharmaceuticals USA
- Ferring to Present New Data Analysis at NASS 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation - Ferring Pharmaceuticals USA
- Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024 - Ferring Pharmaceuticals USA
- Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation - Ferring Pharmaceuticals USA
- View more press releases Close
通过电子邮件
